Moderna, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 1.38M shares, a 57.86% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 1.83M shares, a 11.60% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-06-30 was 1.97M shares, a 63.21% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-03-31 was 1.89M shares, a 40.73% decline year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.22M shares, a 21.29% decline from fiscal 2024.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.55M shares, a 50.16% decline from fiscal 2023.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 3.11M shares, a 34.94% decline from fiscal 2022.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 4.78M shares, a 32.39% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 1.22M shares 10-K · filed 2026-02-20 | |
| 2024-12-31 | 1.55M shares 10-K · filed 2025-02-21 | |
| 2023-12-31 | 3.11M shares 10-K · filed 2024-02-23 | |
| 2022-12-31 | 4.78M shares 10-K · filed 2023-02-24 | |
| 2021-12-31 | 1.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 7.07M shares 10-K · filed 2022-02-25 |
| 2021-09-30 | 1.83M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 8.97M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 1.97M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 9.21M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 1.89M shares 10-Q · filed 2021-05-06 | 12.59M shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 3.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 13.89M shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 2.07M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | 14.00M shares derived: sum of 4 quarters · filed 2020-10-30 |
| 2020-06-30 | 5.35M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 14.44M shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 3.19M shares 10-Q · filed 2020-05-07 | 10.13M shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 3.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 6.95M shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 2.50M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | |
| 2019-06-30 | 1.05M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | |
| 2019-03-31 | 5.53K shares 10-Q · filed 2019-05-09 | |
| 2018-12-31 | 446.86K shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |